主要文件

查看所有文档

O5015

盐酸奥昔布宁

Name: 盐酸奥昔布宁
Brand: SIAL

meets EP, USP testing specifications

别名:

α-苯基环己烷乙醇酸 4-(二乙基氨基)-2-丁炔酯盐酸盐

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₃₁NO₃ · HCl

化学文摘社编号:

1508-65-2

分子量:

393.95

NACRES:

NA.21

PubChem Substance ID:

24898008

UNSPSC Code:

12161900

EC Number:

216-139-7

MDL number:

MFCD00072150

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

200

agency

USP/NF, meets EP testing specifications, meets USP testing specifications

form

solid

application(s)

pharmaceutical (small molecule)

storage temp.

room temp

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

Gene Information

human ... CHRM2(1129), CHRM3(1131)

说明

Biochem/physiol Actions

毒蕈碱型乙酰胆碱受体拮抗剂。

毒蕈碱型乙酰胆碱受体拮抗剂；可能通过下调生长促进基因，抑制膀胱平滑肌细胞的增殖。

Still not finding the right product?

Explore all of our products under 盐酸奥昔布宁

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.

K-S Lee et al.

International journal of clinical practice, 66(7), 663-670 (2012-06-16)

Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.

An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.

Lorne E Aaron et al.

Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)

Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for

Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves.

Jessica T Casey et al.

The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)

Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled

查看所有相关文献

全球贸易项目编号

货号	GTIN
O5015-1G	04061826695128
O5015-5G	04061833429235
O5015-500MG	04061833435571